167 related articles for article (PubMed ID: 37298119)
21. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells.
Yip-Schneider MT; Nakshatri H; Sweeney CJ; Marshall MS; Wiebke EA; Schmidt CM
Mol Cancer Ther; 2005 Apr; 4(4):587-94. PubMed ID: 15827332
[TBL] [Abstract][Full Text] [Related]
22. The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells.
Dai Y; Guzman ML; Chen S; Wang L; Yeung SK; Pei XY; Dent P; Jordan CT; Grant S
Br J Haematol; 2010 Oct; 151(1):70-83. PubMed ID: 20701602
[TBL] [Abstract][Full Text] [Related]
23. Sulforaphane suppresses TNF-alpha-mediated activation of NF-kappaB and induces apoptosis through activation of reactive oxygen species-dependent caspase-3.
Moon DO; Kim MO; Kang SH; Choi YH; Kim GY
Cancer Lett; 2009 Feb; 274(1):132-42. PubMed ID: 18952368
[TBL] [Abstract][Full Text] [Related]
24. Investigating chemoresistance to improve sensitivity of childhood T-cell acute lymphoblastic leukemia to parthenolide.
Ede BC; Asmaro RR; Moppett JP; Diamanti P; Blair A
Haematologica; 2018 Sep; 103(9):1493-1501. PubMed ID: 29773592
[TBL] [Abstract][Full Text] [Related]
25. Nuclear factor-kappaB inhibition by parthenolide potentiates the efficacy of Taxol in non-small cell lung cancer in vitro and in vivo.
Zhang D; Qiu L; Jin X; Guo Z; Guo C
Mol Cancer Res; 2009 Jul; 7(7):1139-49. PubMed ID: 19584264
[TBL] [Abstract][Full Text] [Related]
26. Parthenolide induces apoptosis by activating the mitochondrial and death receptor pathways and inhibits FAK-mediated cell invasion.
Kwak SW; Park ES; Lee CS
Mol Cell Biochem; 2014 Jan; 385(1-2):133-44. PubMed ID: 24065392
[TBL] [Abstract][Full Text] [Related]
27. Anticancer activity of Honokiol against lymphoid malignant cells via activation of ROS-JNK and attenuation of Nrf2 and NF-κB.
Gao DQ; Qian S; Ju T
J BUON; 2016; 21(3):673-9. PubMed ID: 27569089
[TBL] [Abstract][Full Text] [Related]
28. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity.
Yip KH; Zheng MH; Feng HT; Steer JH; Joyce DA; Xu J
J Bone Miner Res; 2004 Nov; 19(11):1905-16. PubMed ID: 15476591
[TBL] [Abstract][Full Text] [Related]
29. Parthenolide and costunolide reduce microtentacles and tumor cell attachment by selectively targeting detyrosinated tubulin independent from NF-κB inhibition.
Whipple RA; Vitolo MI; Boggs AE; Charpentier MS; Thompson K; Martin SS
Breast Cancer Res; 2013; 15(5):R83. PubMed ID: 24028602
[TBL] [Abstract][Full Text] [Related]
30. Parthenolide induces apoptosis in glioblastomas without affecting NF-kappaB.
Anderson KN; Bejcek BE
J Pharmacol Sci; 2008 Feb; 106(2):318-20. PubMed ID: 18277052
[TBL] [Abstract][Full Text] [Related]
31. Parthenolide reduces cisplatin-induced renal damage.
Francescato HD; Costa RS; Scavone C; Coimbra TM
Toxicology; 2007 Jan; 230(1):64-75. PubMed ID: 17156909
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide.
Patel NM; Nozaki S; Shortle NH; Bhat-Nakshatri P; Newton TR; Rice S; Gelfanov V; Boswell SH; Goulet RJ; Sledge GW; Nakshatri H
Oncogene; 2000 Aug; 19(36):4159-69. PubMed ID: 10962577
[TBL] [Abstract][Full Text] [Related]
33. Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-κB Activation.
Kim SL; Kim SH; Park YR; Liu YC; Kim EM; Jeong HJ; Kim YN; Seo SY; Kim IH; Lee SO; Lee ST; Kim SW
Mol Cancer Res; 2017 Feb; 15(2):141-151. PubMed ID: 28108625
[TBL] [Abstract][Full Text] [Related]
34. Parthenolide enhances dacarbazine activity against melanoma cells.
Koprowska K; Hartman ML; Sztiller-Sikorska M; Czyz ME
Anticancer Drugs; 2013 Sep; 24(8):835-45. PubMed ID: 23797801
[TBL] [Abstract][Full Text] [Related]
35. Parthenolide, an inhibitor of the nuclear factor-kappaB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents.
Sheehan M; Wong HR; Hake PW; Malhotra V; O'Connor M; Zingarelli B
Mol Pharmacol; 2002 May; 61(5):953-63. PubMed ID: 11961112
[TBL] [Abstract][Full Text] [Related]
36. Parthenolide complements the cell death-inducing activity of doxorubicin in melanoma cells.
Wozniak M; Szulawska-Mroczek A; Hartman ML; Nejc D; Czyz M
Anticancer Res; 2013 Aug; 33(8):3205-12. PubMed ID: 23898080
[TBL] [Abstract][Full Text] [Related]
37. Rosmarinic acid sensitizes cell death through suppression of TNF-alpha-induced NF-kappaB activation and ROS generation in human leukemia U937 cells.
Moon DO; Kim MO; Lee JD; Choi YH; Kim GY
Cancer Lett; 2010 Feb; 288(2):183-91. PubMed ID: 19619938
[TBL] [Abstract][Full Text] [Related]
38. Parthenolide, an inhibitor of the nuclear factor-κB pathway, ameliorates dextran sulfate sodium-induced colitis in mice.
Zhao ZJ; Xiang JY; Liu L; Huang XL; Gan HT
Int Immunopharmacol; 2012 Jan; 12(1):169-74. PubMed ID: 22155740
[TBL] [Abstract][Full Text] [Related]
39. NF-κB-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT.
Nakshatri H; Appaiah HN; Anjanappa M; Gilley D; Tanaka H; Badve S; Crooks PA; Mathews W; Sweeney C; Bhat-Nakshatri P
Cell Death Dis; 2015 Jan; 6(1):e1608. PubMed ID: 25611383
[TBL] [Abstract][Full Text] [Related]
40. Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition.
Zha J; Chen F; Dong H; Shi P; Yao Y; Zhang Y; Li R; Wang S; Li P; Wang W; Xu B
J Transl Med; 2014 Jun; 12():163. PubMed ID: 24915933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
